Pahuja Priyanka, Kashyap Heena, Pawar Pravin
Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala Highway, Rajpura, Patiala, Punjab, India, 140401.
Curr Drug Deliv. 2014;11(2):223-32. doi: 10.2174/1567201810666131224105205.
Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
新型抗真菌药物伏立康唑的全身给药会产生包括视觉障碍和肝脏异常在内的不良反应。本研究的目的是使用2-羟丙基-β-环糊精(HP-β-CD)提高伏立康唑的水溶性,并研究向这些溶液中添加粘度调节剂的效果。采用单因素方差分析和Dunnett检验进行统计分析。相溶解度研究表明,伏立康唑的溶解度随HP-β-CD浓度的增加而增加。在基于伏立康唑-HP-β-CD的滴眼液(1.5%,pH 7.0)中使用0.2%壳聚糖、0.01%苯扎氯铵(BAK)和0.01%乙二胺四乙酸(EDTA)的组合,与不含壳聚糖的制剂和对照制剂(不含壳聚糖和防腐剂)相比,表观渗透系数(Papp)分别提高了3.9倍和5.4倍。因此,可以得出结论,使用HP-β-CD配制的伏立康唑滴眼液可局部用于治疗真菌性角膜炎,并且向伏立康唑滴眼液中添加壳聚糖可显著提高渗透率。